Previously available only as an injection, the anti-obesity drug Wegovy is now marketed in France in tablet form. It is the first oral treatment in the GLP-1 family, a class of medications that regulates appetite and promotes weight loss.
Already sold in the United States, the United Kingdom, and Germany, this treatment is intended for obese or overweight adults suffering from at least one weight-related condition. Not currently covered by health insurance, its cost ranges from €169 to €235 per month depending on the dosage.
Nearly 100,000 patients are already using Wegovy in France. According to Novo Nordisk, this new oral form aims primarily to broaden access to the treatment rather than replace injections.
Its approval is based on studies showing weight loss of up to 17% after approximately fifteen months of high-dose treatment.
This arrival comes amid fierce competition from the American company Eli Lilly, which is preparing the European launch of its own oral treatment, Foundayo. The two pharmaceutical companies are vying for a global obesity market estimated to exceed $100 billion by 2030.
To maintain their lead, these companies are already developing new generations of medications, aiming for increased efficacy, fewer side effects, less frequent dosing, and better preservation of muscle mass.
In parallel, Novo Nordisk is also launching a higher-dose injectable version of Wegovy in France. Obesity currently represents an estimated medical and socio-economic cost of €18 billion per year in France.
 Sophie de Duiéry
|
02/11/2026 | 
Anglais
Arabic
Deutsch
Français
Español
Italien
Português
Russian